Radisens appoints Kevin Fielding and Gary Kennedy to Board
CORK, Ireland — Jan 25, 2010 — Radisens Diagnostics, a medical diagnostics company developing portable diagnostic platforms for point-of-care, is pleased to announce the appointed of Kevin Fielding and Gary Kennedy to its Board as independent Non-Executive Directors.
Kevin joined Alta Berkeley VC in 2003 and has a 20-year track-record of building and managing technology companies in both Europe and the US. Prior to joining Alta Berkeley, Kevin held the position of President and CEO of ParthusCeva. He also led several successful high-technology start-up activities, including Parthus Technologies which had a successful IPO on the LSE and NASDAQ in 2000, and the StrongARM microprocessor business, acquired by Intel in 1998. Prior to returning to Europe in 1998, Kevin spent 10 years working on several high-tech businesses. He was the General Manager of the StrongARM business in Palo Alto, CA prior to its acquisition by Intel in 1998, and also worked on the original Alpha microprocessor for Digital Equipment Corporation. Before moving to the United States, Kevin worked on high-speed processor design for Philips BV in Eindhoven and in Dublin. He also spent four years working in the research labs at the NMRC (National Microelectronics Research Centre) attached to University College, Cork, Ireland.
Gary was Group Director, Finance & Enterprise Technology, at Allied Irish Banks (AIB) from May 1997 to December 2005, was a member of the main Board of AIB and was also on the Board of M&T, AIB’s associate in the United States. Prior to that, Gary was Group Vice President at Nortel Networks Europe after starting his management career at Deloitte & Touche. He served on the Board of the Industrial Development Authority (IDA) of Ireland for 10 years until he retired in December 2005. Gary was appointed a Director of Elan plc in May 2005, and is also a Director of Greencore Group. He is Chairman of a number of private companies. Gary is a chartered accountant.
“We are delighted to welcome both Kevin and Gary on board, leveraging their proven track records of positioning startups for high growth, attracting the necessary funding and implementing strong corporate governance” commented Jerry O’Brien, Radisens CEO. “Having such high calibre members on our Board is a testament to our progress towards handheld haematology analysers”
About Radisens Diagnostics
Radisens develops portable diagnostic platforms for point-of-care, resulting in rapid and reliable laboratory-grade blood testing across multiple assays. Radisens is miniaturizing gold-standard clinical laboratory diagnostic instrumentation and developing a consummable suite covering immunoassay, haematology and molecular diagnostic tests. No solution on the market offers a multiplexed, quantitative platform for blood testing across such a wide range of applications in a single portable, battery-operated instrument. This patent pending disruptive technology will drive a step change towards ubiquitous rapid handheld analysis in GP clinics, outpatient and emergency room settings.